Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Alzheimer's Disease Clinical Trials

A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (58) clinical trials

The primary objective of the study is to evaluate the efficacy of monthly doses of Aducanumab in slowing cognitive and functional impairment.

Phase

The study will evaluate the efficacy, safety, and tolerability of a medication: AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type. Approximately 325 patients will be enrolled at approximately 50 centers in North America.

Phase

This is a study to test the safety and tolerability of the research study drug, suvorexant and test the effects of suvorexant compared to placebo in improving insomnia in subjects with mild to moderate Alzheimer’s disease.

Phase

Evaluate the efficacy of Lanabecestat in mild Alzheimer's Disease dementia   Other Details:  https://clinicaltrials.gov/ct2/show/study/NCT02783573

Phase

Study Description: CREAD2 is a Phase 3 study investigating the effect of an investigational drug in the form of an infusion on Alzheimer's disease progression in individuals with prodromal to mild Alzheimer's disease. The study drug, crenezumab, is a monoclonal antibody that targets amyloid-beta proteins in the brain. The study ...

Phase

This study is for participants that have been diagnosed with a mild to moderate form of Alzheimer's disease (AD). This research involves an experimental study drug known as LY2062430. The primary objective of this study is to test whether LY2062430 will slow the rate of mental (thinking and remembering) decline ...

Phase

NeuroTrials Research is conducting a 20-month, placebo-controlled research study evaluating an investigational drug for Alzheimer’s Disease. Study-related exams and study drug are provided at no cost. Qualified participants and caregivers will be compensated for time and travel. Patient Inclusion Criteria: Age 50-89 Diagnosis of probable Alzheimer’s Disease Must have a ...

Phase

Patient Inclusion Criteria: Ages: over 66-85 Male/Female 26 Double Blind Period, Optional 26 week Long Extension No History of Cancer within past 5 years Dementia status of mild to moderate CT or MRI scan within 18 months prior to screening compatible with a diagnosis of probable Alzheimer's disease Score on ...

Phase

This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer's Disease Inclusion Criteria: Dementia status of mild to moderate CT or MRI scan within 18 months prior ...

Phase

EXPEDITION 3 will look at whether the investigational drug solanezumab can help slow the worsening of AD in patients with mild disease. Study duration will be approximately 18 months, followed by an optional open-label extension study. Participants will be randomized in a 1:1 ratio to receive solanezumab or placebo by ...

Phase